Cancer Clinical Trials Results
|CASE 1213||041322C||A Pharmacodynamic Study of Metformin in Patients with Resectable Pancreatic Cancer||Main Campus|| || ||Pancreas
|CASE 9212||12-1317||Outcomes Registry of Patients with Pancreatic Cancer Undergoing Definitive Treatment at Cleveland Clinic||Main Campus|| || ||Pancreas
|CLGN 1214||14-468||A Phase 3, multicenter, open-label, randomized study of nab®-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma||Main Campus|| ||Phase 3||Pancreas
|ECOG 2211||13-1201||A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors||Beachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster|| ||Phase 2||Pancreas
|OMP 1213||14-124||A Phase 1b/2 Study of OMP-59R5 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Stage IV Pancreatic Cancer ALPINE: Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety||Main Campus||Stage 4||Phase 1, Phase 2||Pancreas
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2014 Cleveland Clinic. All rights reserved.